The antibody cocktail from Regeneron is authorized for treating mild to moderate COVID-19 in adults, as well as pediatric patients at least 12 years old who have a high risk of progressing to severe disease.

The company said it could have enough doses for around 80,000 patients by the end of November, and enough for approximately 300,000 patients in total by the end of January.

Regeneron CEO Leonard S. Schleifer said in a statement that the emergency authorization is “an important step in the fight against COVID-19,” adding that “the science and technology investments Regeneron has made over three decades positioned us to move rapidly to invent, study and maximize production” of the cocktail.